Table 1

Characteristics of studies included in this systematic review

Author	Year	Country	Study design	Clinical setting	Outcome	Measured timing	Sample size (n)	Source of sample	Male (%)	Age (years)	Patient population	Mortality (%)	Cut-off (pg/mL)	TP	FP	FN	TN	SEN (95% CI)	SPE (95% CI)
Su17	2012	China	PR	ICU	28-day mortality	D1	80	Serum	65	62±19	Sepsis	51.3	449	26	6	15	32	64.3	84.2
Li20	2014	China	PR	ICU	28-day mortality	D1	102	Serum	48	63±21	Sepsis	41.2	252.05	36	15	6	15	85.7	71.4
Gibot34	2005	France	PR	Medical ICU	28-day mortality	D0	63	Serum	59	61±14	Sepsis	33	180	18	13	3	29	85.7	90.6
Latour-Perez35	2010	Spanish	PR	ICU	28-day mortality	D1	121	Serum	43	55–78	Sepsis	24.8	90	14	20	16	71	47	78
Kofoed36	2008	Denmark	PR+CR	HW	30-day mortality	D1	151	Serum	48.3	56 (20–94)	Suspected infection	6	9000	9	85	0	51	100	36
Sun37	2011	China	PR	ICU	28-day mortality	D1	50	Serum	60	66±17	Sepsis	32	50	13	9	3	25	83.8	86.3
Wu38	2011	Taiwan	PR	ICU	ICU mortality	D1	27	BAL fluid	74.1	72.52±8.16	VAP	63	44	7	5	3	12	70	70.6
Chen39	2009	Taiwan	PR+CR	ICU	28-day mortality	D1	88	Serum	87.5	74.6±12.0	ARDS	61.4	42	34	14	20	20	63	58.8
Huang40	2014	Taiwan	PR	HW	6-month mortality	D1	243	Serum	68	62.1±17.9	Tuberculosis	16	129	31	69	8	135	79.5	66.2

ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; CR, mean consecutive recruitment; FN, false negative; FP, false positive; HW, hospital ward; ICU, intensive care unit; PR, mean prospective recruitment; SEN, sensitivity; SPE, specificity; TN, true negative; TP, true positive; VAP, ventilator-associated pneumonia.